Back to Agenda
Session 5: Biosimilars Role in Healthcare Recovery, Disparities, and Equity
Session Chair(s)
Julie Marechal-Jamil, MSC
Director, Biosimilar Policy and Science, Medicines For Europe, Belgium
Optimal patient care and Healthcare systems sustainability are both part of a difficult equation to manage, and recent months have showed that resilience needs to be further built in to ensure equity in access to care. There are many roads to efficiency in healthcare. One of them involves optimal use of biosimilar medicines. There is growing evidence that biosimilar medicines use has already allowed smart re-investment of healthcare funds into: broader access (more patients treated), earlier access in the treatment course (lifting cost-related restrictions) but also funding of new therapeutics or supportive care, or healthcare staff, infrastructure or services.
Learning Objective : At the conclusion of this session, participants should be able to:
- Explain the value of biosimilar medicines for healthcare & patient care beyond price competition
- Illustrate - with concrete examples - the biosimilar experience in creating broader, earlier and future access to biologic medicines and healthcare
- Compare and contrast the opportunities depending on the therapy area and patient treatment course (i.e. cancer, diabetes)
Speaker(s)
Pam Traxel
Senior Vice President, American Cancer Society Cancer Action Network, United States
Living with Cancer in the US – Opportunities for Better Access Equity and Affordability of Care
Erika Benke Emerson, MPA
Chief Policy Officer, Diabetes Leadership Council, United States
Living with Diabetes in the US – Opportunities for Better Access Equity and Affordability of Care
Paul Cornes, MD
Oncologist, Bristol Oncology Centre, United Kingdom
Revealing the Value Biosimilar Medicines
Have an account?